940.F EUROAPI SAS EO 1
- Market cap
- EUR 73.9M
- P/E
- -
- P/B
- 0.11x
- ROE
- -26.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 940.F undervalued?
Graham numberThe Graham number of EUROAPI SAS EO 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EUROAPI SAS EO 1 fundamental analysis
No fundamental analysis for EUROAPI SAS EO 1 yet.
EUROAPI SAS EO 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EUROAPI SAS EO 1
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostag…
Full company profileEUROAPI SAS EO 1 financial statements
EUROAPI SAS EO 1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 893M | 981M | 1.02B | 919M | 853M |
| Gross Profit | 109M | 177M | 165M | 142M | 145M |
| Operating Income | 1.50M | 27.1M | 4.50M | -10.2M | 1.70M |
| EBITDA | - | 102M | 70.7M | -42.5M | 10.0M |
| Net Income | -8.10M | -15.0M | -190M | -131M | -211M |
| EPS | -0.09 | -0.16 | -2.00 | -1.37 | -2.22 |
| Balance Sheet | |||||
| Total Assets | 1.62B | 1.74B | 1.61B | 1.49B | 1.30B |
| Total Liabilities | 606M | 626M | 685M | 506M | 517M |
| Shareholders' Equity | 1.02B | 1.11B | 928M | 984M | 788M |
| Cash & Short-term Investments | 10.3M | 74.5M | 34.5M | 73.0M | 114M |
| Cash Flow | |||||
| Operating Cash Flow | 71.5M | 44.8M | 5.10M | 123M | 129M |
| Capital Expenditure | 88.6M | 167M | 133M | 108M | 78.5M |
| Free Cash Flow | -17.1M | -123M | -128M | 14.9M | 50.0M |
| Ratios | |||||
| ROE | -0.8% | -1.4% | -20.4% | -13.3% | -26.8% |
| ROA | -0.5% | -0.9% | -11.8% | -8.8% | -16.2% |
| Net Profit Margin | -0.9% | -1.5% | -18.6% | -14.2% | -24.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EUROAPI SAS EO 1 dividends
EUROAPI SAS EO 1 has not paid dividends in the last 5 fiscal years.
Who owns EUROAPI SAS EO 1
- Insiders 34.84%
- Institutions 35.58%
- Public & others 29.59%
- Shares outstanding 95.5M
- Free float 50.8M
EUROAPI SAS EO 1 company profile
- Company name
- EUROAPI SAS EO 1
- Ticker
- 940.F
- ISIN
- FR0014008VX5
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 32 rue Alexandre Dumas, Paris, France, 75011
- Phone
- 33 1 23 45 67 89
- Website
- euroapi.com
About EUROAPI SAS EO 1
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
EUROAPI SAS EO 1 management
10- Mr. David SeignolleChief Executive Officer · born 1983
- Mr. Olivier FalutChief Financial Officer
- Mr. Jean-Francois BlancChief Operating Officer
- Sophie PalliezHead of Investor Relations
- Ms. Marion SantinChief Legal, Compliance, & IP Officer
- Ms. Raphaele HauzyChief People Officer
- Mr. Frederic LelievreChief Quality Officer
- Ms. Sylvia Cabrillac-RivesChief Strategy Officer
- Mr. Frederic RobertChief Commercial Officer
- Mr. Laurent PetitChief Research & Development Officer